Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications NK Cells G-Rex®100

Publication Date: January 1, 2014

Clinical Grade Purification and Expansion of Natural Killer Cells

Clinical-grade natural killer cell manufacturing can be achieved by CliniMACS-based enrichment or by feeder-cell expansion, and this review describes both along with the authors' own GMP process for multiple myeloma trials. CD3 depletion alone yields about 20% purity, CD56 selection more than 95%, and feeder-based expansion reaches over 70% purity within 10–14 days. The authors expand NK cells with irradiated K562-41BBL-mbIL-15 feeders in G-Rex®100 flasks seeded with 5×10^6 NK cells, harvesting on days 8 to 10 with up to 5×10^8 cells per flask. Side-by-side WAVE bioreactor cultures gave similar yields and potency. Products formulated for infusion and shipped on ice packs retained viabilit…

Download Now →

Author: Natalia Lapteva, Susann M. Szmania +2 more

Publications CAR T Cells G-Rex®100M

Publication Date: November 28, 2013

Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells

Targeting two tumor antigens at once improves CAR T-cell killing of pancreatic cancer cells but still does not eradicate them, because cells with low antigen density escape. T cells carrying CARs against PSCA or MUC1 killed CAPAN1 cells, yet tumors regrew in mice. In a 72-hour coculture, the combination reduced tumor cells by 96.6%, against 65% for CAR-MUC1 and 82.1% for CAR-PSCA, but tumor recurred in all mice by day 63. In engineered 293T mixtures, cells with the highest antigen levels were killed first and low expressers survived. Decitabine raised MUC1 expression and resensitized resistant tumor cells to CAR-MUC1 T cells.

Download Now →

Author: Usanarat Anurathapan, Robert C Chan +10 more

Publications VST Cells

Publication Date: November 7, 2013

Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients

Donor-derived pentavalent T cell lines targeting five viruses (EBV, adenovirus, CMV, BK and HHV6) were generated rapidly and infused into stem cell transplant recipients, proving safe so far and associated with virus clearance. Lines were stimulated once with peptide libraries and expanded with IL4+7 in a G-Rex® device; from 30×10^6 PBMCs, a mean of 374×10^6 cells was obtained over 9-11 days, with 35 clinical-grade lines generated. The cells were polyclonal, with CD4+ 57±5% and CD8+ 35±5%, and showed no alloreactivity against recipient PHA blasts. Ten patients on study received cells at three dose levels with no adverse events; by day 42, viral load showed control of active CMV, EBV, Adv,…

Download Now →

Author: Anastasia Papadopoulou, Usha Katari +11 more

Publications NK Cells G-Rex®100

Publication Date: October 18, 2013

Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity

Unselected cord blood mononuclear cells co-cultured with K562-based artificial antigen presenting cells expressing membrane-bound IL-21 and 100 IU/mL IL-2 in a GP500 gas-permeable bioreactor yielded log-scale NK cell expansion in 14 days. Twenty million MNCs were plated in 400 mL with irradiated feeders at 2:1, CD3-depleted on day 7 and restimulated 7 more days. Fresh CB (n = 8) expanded NK cells a mean 1848-fold and frozen CB (n = 6) 2389-fold, versus 20-fold for CD56-selected cells with IL-2 alone (n = 3); the product was 96% CD56+/CD3- with under 1% CD3+ cells. Expanded CB-NK cells killed myeloma lines RPMI 8226, ARP-1 and U266 in vitro; in NSG mice bearing ARP-1 myeloma, three doses o…

Download Now →

Author: Nina Shah, Beatriz Martin-Antonio +19 more

Publications CAR T Cells, VST Cells

Publication Date: October 4, 2013

Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes without enhancement of regulatory T-cell inhibition

IL-7 selectively supported EBV-specific cytotoxic T cells engineered with a GD2-targeted CAR and IL-7Rα, even when regulatory T cells were present. EBV-CTLs from 5 donors expressed CAR-GD2 and IL-7Rα in 64% and 34% of cells. With IL-7, transduced cells proliferated far more than control cells (63% versus 14%), while expanded Tregs lacked IL-7Rα and did not proliferate with IL-7. In co-culture with neuroblastoma cells and Tregs, residual tumor cells were 14% with IL-2 but 7% with IL-7. In NSG mice, IL-7 kept tumor control equal with or without Tregs (1.3 × 10^8 versus 1.2 × 10^8 photons at day 34), whereas IL-2 control was abrogated by Tregs (2.4 × 10^8 photons).

Download Now →

Author: Serena K. Perna, Daria Pagliara +5 more

Publications CTL Cells

Publication Date: July 9, 2013

Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia – implications for immunotherapy

Tumor-associated antigen-specific T-cell lines could be generated from all 50 children with acute lymphoblastic leukemia sampled during maintenance chemotherapy, regardless of NCI risk group or lymphocyte count. Peripheral blood mononuclear cells were stimulated with autologous dendritic cells pulsed with peptide libraries of WT1, Survivin, MAGE-A3 and PRAME, then restimulated with peptide-pulsed PHA-blasts. Expansion after three stimulations ranged from 1.2- to 31.4-fold (mean 6.4-fold). Responses against at least one antigen were found in 92% of standard-risk and 96% of high-risk patients. The lines were predominantly CD3-positive effector-memory cells (mean CD3 97.2%). In co-culture wi…

Download Now →

Author: Gerrit Weber, Ignazio Caruana +6 more

Publications CTL Cells, VST Cells G-Rex®10

Publication Date: June 20, 2013

Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant

Donor-derived T cells targeting Epstein-Barr virus, cytomegalovirus and adenovirus can be generated in a single 9–11-day culture without live virus or viral vectors, and they cleared infections in most transplant recipients treated. Dendritic cells nucleofected with plasmids encoding viral antigens stimulated 15 × 10^6 PBMCs, and expansion in G-Rex®10 devices with IL4 and IL7 gave a median of 212.5 × 10^6 cells across 36 lines. Ten allogeneic transplant recipients with CMV, Adv or EBV infections received 0.5–2 × 10^7 cells/m2; eight had complete responses, including all four with dual infections, and falling viral loads coincided with rising frequencies of virus-specific T cells. No line…

Download Now →

Author: Ulrike Gerdemann, Usha L Katari +13 more

Publications TIL Cells

Publication Date: May 20, 2013

Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies

Autologous tumor-infiltrating lymphocyte therapy produced durable responses in refractory metastatic melanoma, including patients who had failed earlier immunotherapies. Of 80 enrolled stage IV patients, 57 received unselected TIL after nonmyeloablative conditioning and high-dose IL-2; objective responses occurred in 40% of treated and 29% of enrolled patients, with 5 complete remissions. Median overall survival from TIL infusion was 15.2 months, and 78% of responders were alive at 3 years. Shorter culture time, higher infused CD8+ cell numbers, male gender and normal LDH were associated with response. Prior ipilimumab failure did not reduce response, with 38% responding among patients wh…

Download Now →

Author: Michal J. Besser, Ronnie Shapira-Frommer +18 more

Publications TIL Cells

Publication Date: May 6, 2013

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

In a randomized selection design trial of 69 melanoma patients, CD8+-enriched TILs were not more effective than unselected young TILs for adoptive cell therapy. Thirty-four patients received unselected young TILs and 35 received CD8+-enriched TILs after nonmyeloablative lymphodepletion and high-dose IL-2. Objective responses occurred in 12 patients (35%) with unselected TILs and seven (20%) with CD8-enriched TILs, a difference that was not significant. Patients given enriched cells had fewer circulating CD4+ lymphocytes one month later. Response was associated with interferon gamma release by infused TILs against autologous tumor. TIL products were generated for 67% of eligible patients,…

Download Now →

Author: Mark E. Dudley, Colin A. Gross +16 more

Publications NK Cells

Publication Date: January 1, 2013

Improved Homing to Bone Marrow, Spleen and Lung of Adoptively Infused NK Cells Expanded Ex Vivo with the Small Molecule Nicotinamide Using Feeder-Free Conditions

Culturing donor NK cells with nicotinamide (NAM) in feeder-free conditions improved their homing to bone marrow, spleen and lung after infusion into mice. CD3-depleted apheresis cells were grown for two weeks in G-Rex® devices in medium with human serum and IL-2 or IL-15, with or without 5 mM NAM, without feeder cells or feeding. A large-scale run seeded 3.5 × 10^9 cells and gave about 4-fold total expansion and 50-fold NK expansion, with more than 96% NK cells and under 0.3% T cells. Apart from CD62L, NK phenotype did not differ consistently between expansion methods. In an irradiated NSG myeloma model, mice given tumor cells but no NK cells became paraplegic, so all were sacrificed on d…

Download Now →

Author: Gabi Frei, Maria Berg +9 more

Publications Treg Cells G-Rex®10, G-Rex®100

Publication Date: December 14, 2012

Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease

A simple, cost-effective protocol using gas-permeable G-Rex® flasks expanded human naturally occurring regulatory T cells (nTregs) to clinically relevant numbers while preserving function. CD25-bright cells selected from healthy-donor buffy coats were activated with anti-CD3/CD28 and temsirolimus, then expanded with irradiated allogeneic feeders and IL-2 in two successive G-Rex® passages over 21 days. More than 10^9 cells were obtained, with 92±5% CD4+CD25+ and 69±19% FoxP3+ cells. Expanded cells inhibited CD8+ cell division by 80±13% in vitro. In a xenograft mouse model with 12 animals per group, they improved survival and body weight compared with control CD25-depleted cells. A validati…

Download Now →

Author: Rikhia Chakraborty, Aruna Mahendravada +6 more

Publications NK Cells G-Rex®10, G-Rex®100

Publication Date: August 17, 2012

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications

NK cells can be expanded more than 100-fold in static G-Rex® gas-permeable flasks without medium exchange, offering a simpler route to clinical-scale doses than gas-permeable bags. Peripheral blood mononuclear cells were co-cultured for 8 to 10 days with irradiated K562-mb15-41BBL feeder cells and 10 U/mL IL-2. In G-Rex®100 flasks seeded with 4 × 10^6 NK cells, expansion averaged 175-fold, and in a side-by-side comparison G-Rex® flasks gave higher fold expansion than bags without interim feeding. Clinical-scale runs produced up to 19 × 10^9 NK cells from 15 × 10^7 seeded cells. Contaminating T cells (less than 35%) could be removed by magnetic depletion, and cryopreserved NK cells remaine…

Download Now →

Author: Natalia Lapteva, April G. Durett +18 more